Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 40
- Registration Number
- NCT01324336
- Locations
- 🇺🇸
The Children's Mercy Hospital, Kansas City, Missouri, United States
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: AlemtuzumabProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Etoposide PhosphateBiological: FilgrastimDrug: Fludarabine PhosphateProcedure: In Vitro-Treated Peripheral Blood Stem Cell TransplantationOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MelphalanDrug: MercaptopurineDrug: MethotrexateBiological: PegfilgrastimOther: Pharmacological StudyDrug: TacrolimusDrug: Vincristine Sulfate
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT01256398
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
🇺🇸Longmont United Hospital, Longmont, Colorado, United States
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 573
- Registration Number
- NCT01230983
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
- Conditions
- Interventions
- Drug: AmsacrineDrug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: DexamethasoneDrug: Daunorubicin hydrochlorideDrug: Doxorubicin hydrochlorideDrug: Etoposide phosphateDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine sulfateRadiation: Whole-brain radiation therapy
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 745
- Registration Number
- NCT01228331
- Locations
- 🇩🇪
Universitaetsklinikum Duesseldorf, Duesseldorf, Germany
🇩🇪University Medical Center Hamburg - Eppendorf, Hamburg, Germany
🇩🇪Johannes Gutenberg University, Mainz, Germany
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
- Conditions
- Ann Arbor Stage I B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaAdult B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Down SyndromeHypodiploid B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome PositiveAnn Arbor Stage II B Lymphoblastic LymphomaChildhood B Lymphoblastic Lymphoma
- Interventions
- Drug: DexamethasoneDrug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: MethotrexateDrug: Doxorubicin HydrochlorideOther: Quality-of-Life AssessmentOther: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationDrug: Leucovorin CalciumDrug: Vincristine SulfateDrug: PegaspargaseDrug: Thioguanine
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 9350
- Registration Number
- NCT01190930
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2021-09-13
- Target Recruit Count
- 76
- Registration Number
- NCT01156883
- Locations
- 🇮🇹
Azienda Ospedaliera - Nuovo Ospedale "Torrette", Ancona, Italy
🇮🇹USL 8 - Ospedale S.Donato, Arezzo, Italy
🇮🇹UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: PEG-L-asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: mercaptopurineDrug: ifosfamideDrug: methotrexateDrug: vincristine sulfateDrug: prednisoneRadiation: Radiation TherapyDrug: thioguanineDrug: vindesineDrug: daunoxomeDrug: fludarabine
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 6136
- Registration Number
- NCT01117441
- Locations
- 🇦🇹
A.oe. Landeskrankenhaus Klagenfurt, Abt. für Kinder- und Jugendheilkunde, Klagenfurt, Austria
🇨🇿University Hospital Brno, Department of Pediatric Oncology, Brno, Czechia
🇩🇪Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie, Berlin, Germany
Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: rituximabBiological: paliferminDrug: cyclophosphamideProcedure: allogeneic hematopoietic stem cell transplantationDrug: cytarabineDrug: daunorubicin hydrochlorideRadiation: total-body irradiationDrug: etoposideDrug: fludarabine phosphateDrug: imatinib mesylateDrug: melphalanDrug: mercaptopurineDrug: methotrexateDrug: nelarabineDrug: pegaspargaseDrug: vincristine sulfate
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1033
- Registration Number
- NCT01085617
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 180
- Registration Number
- NCT01005758
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 106
- Registration Number
- NCT00866918
- Locations
- 🇺🇸
Overlook Hospital, Summit, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.